Nuveen
NKTR icon

Nuveen’s Nektar Therapeutics NKTR Stock Holding History

Nuveen’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,747
Closed -$4K – 3236
2019
Q4 		$4K Buy
+13,747
New +$3.99M ﹤0.01% 3210

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's NKTR Position: Q2 2026 in Review

Nuveen opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 96,636 shares worth $6.75M. The stake represents ﹤0.01% of the portfolio and ranks #1932 among its holdings. This is a return to the name: Nuveen previously reported a position in NKTR as recently as Q1 2025.

Nuveen first reported a position in NKTR in Q3 2013 and has held it in 33 quarters since. The position peaked at $33.3M in Q2 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Nuveen held 96,636 shares of Nektar Therapeutics worth $6.75M as of Q2 2026.
  • Nektar Therapeutics was a new Nuveen position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1932 holding.
  • Nuveen first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 33 quarters since.
  • Nuveen's Nektar Therapeutics position peaked at $33.3M in Q2 2019.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.